A novel AI-powered retina tracker can analyze retinal images with near-perfect accuracy in under one second, according to a study being presented Monday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif. The researchers say the findings offer hope for sight-saving screenings for diabetic retinopathy and other eye diseases that are fast, affordable, and accessible worldwide.
“The application, an AI-based model integrated into Simple Mobile AI Retina Tracker (SMART), uses cutting-edge deep learning algorithms to analyze retinal fundus images quickly and accurately, on internet-powered devices including basic smartphones,” according to presenting author Jansi Rani Sethuraj, BSN, RN, CCRN, of the University of Texas Health Sciences Center in Houston, Texas. “The SMART AI application enables ophthalmologists to streamline patient screening, empowers primary care providers to incorporate eye exams into routine visits, and expands access to high-quality retinal assessments in regions lacking specialized ophthalmic care.”
Diabetic retinopathy, a leading cause of preventable blindness, affects over 100 million people globally as the incidence and prevalence of diabetes continue to rise worldwide.
Two researchers, Ramya Elangovan and Kavin Elangovan of AIM Doctor in Houston, Texas, sourced several thousand anonymized retinal images from multiple datasets representing diverse populations spanning six continents. These images were used to train and validate deep learning models capable of detecting and staging diabetic retinopathy with over 99% accuracy in under one second. The tracker was also able to differentiate diabetic retinopathy from similar eye pathologies. Healthcare professionals from multiple international institutions independently validated the application’s reliability and usability, underscoring its global applicability.
“By democratizing eye care through universally accessible mobile technology, this innovation has the potential to screen billions globally, reducing vision loss from diabetic retinopathy while transforming healthcare delivery systems,” says the chief mentor of this project, Elangovan Krishnan, MB, BS, PGDHM, MTech, MS, PhD, of AIM Doctor. “This research proves that AI can be a force for good, bridging gaps in care and bringing hope to millions at risk of losing their sight.”
You may also like
EUREKA! The Top Endocrine Science of 2025
For the eleventh year running, Endocrine News talks to editors from Endocrine Society publications to unearth the most impressive breakthroughs in endocrine science and research for 2025. From GLP-1s, adrenal treatments, and acromegaly breakthroughs to obesity, diabetes, and cutting-edge research in reproductive medicine, 2025 was a banner year for endocrine research and researchers! For more…
Tirzepatide Improves Blood Sugar Control in Children Aged 10-17 Years with Type 2 Diabetes
New research shows that that the diabetes/obesity medication tirzepatide can cause clinically meaningful improvements in blood sugar control and weight loss in children and adolescents with type 2 diabetes aged 10-17 years whose diabetes and weight are inadequately controlled with an existing treatment regimen of metformin, insulin, or both. The study (the SURPASS-PEDS trial), led…
